Skip to content

First published Wednesday 25 May 2016.

Mailing list

Be Inspired

Join thousands of active subscribers and hear about the brave children, dedicated researchers, and world-leading science at Telethon Kids Institute.

You can opt-out at any time from this free series.




 

We guarantee 100% privacy. Your information will not be shared.

media enquiries

Media Contacts

Please direct general enquiries to our reception on (08) 6319 1000.

Please direct media enquiries to our media team:

Amy Birch
Senior Communications Officer 
Phone: +61 8 6319 1671 (office) 0437 575 875 (mobile)
Email: Amy Birch

Tammy Gibbs 
Communications Manager 
Phone: +61 8 6319 1645 (office) 0408 946 698 (mobile)
Email: Tammy Gibbs

The Perth team is now negotiating to start a clinical trial of a new class of drugs, which were developed for adult cancer and have never been tested in children.

“The hope is that we’ll find some more treatments which will maximise the effects of the chemotherapy so we can reduce the radiation which has more damaging side-effects on the patient in the long term,” Dr Gottardo said.

  • Medulloblastoma is the most common malignant brain tumour of childhood.
  • The disease affects one in five children who have a brain tumour.
  • Medulloblastoma is curable in approximately 70% of patients.